6 news items
Reviva Provides Enrollment Update For Its Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
RVPH
15 May 24
an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
RVPH
15 May 24
, today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
RVPH
25 Apr 24
15, 2024. If you purchased or otherwise acquired Reviva shares and suffered a loss, are a long-term stockholder, have
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
RVPH
15 Apr 24
-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
RVPH
15 Apr 24
those relating to the Company's 1-year open label extension (OLE) trial evaluating the long-term safety and tolerability for brilaroxazine
gr7pti zi
RVPH
28 Mar 24
Securities Litigation Reform Act, as amended, including those relating to the Company's 1-year open label extension (OLE) trial evaluating the long-term safety
- Prev
- 1
- Next